B7-H3 And PD-1: Are All Checkpoint Inhibitors Created Equal? (MGNX) - Seeking Alpha | Immunology and Biotherapies | Scoop.it
From seekingalpha.com - December 16, 2014 5:19 AM

Checkpoint inhibitors are a big deal. What started with ipilimumab has now grown into a class of drugs which are being pursued vigorously by nearly every major pharmaceutical company in the world. In this crowded space, it's worth noting that B7-H3 is only being pursued by one company, MacroGenics (NASDAQ:MGNX).


Via Krishan Maggon